Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer. Farlow JL, McCrary HC, Sipos JA, Phay JE, et al. Oral Oncol 2023;147:106625.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Farlow JL, McCrary HC, Sipos JA, Phay JE, et al. Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer. Oral Oncol 2023;147:106625.
PMID: 37948895